secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anebulo Pharmaceuticals, Inc. (ANEB)
CIK:        0001815974
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0001493152-23-016291
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anebulo reports Q3 FY2023 net loss of $2.8M ($0.11/share); cash $14.2M; positive Phase 2 data for ANEB-001
--------------------------------------------------------------------------------

- Net loss $2.8M ($0.11 per share) vs $1.9M ($0.08) in Q3 FY2022.
- Operating expenses $2.9M, up from $1.9M year-over-year.
- Cash and cash equivalents $14.2M as of March 31, 2023.
- Announced positive complete Phase 2 data for ANEB-001 in acute cannabinoid intoxication.
- Type B meeting with FDA scheduled for July 2023 to discuss registrational path.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223016291/0001493152-23-016291-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1815974/000149315223016291/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-23-016291

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer